Close Menu

NEW YORK – Illumina said on Friday that it has received medical device registration in Russia for its NextSeq 550Dx sequencing platform, associated reagent kits, and reagents for the MiSeq Dx sequencer, which was previously approved in Russia.

R-Pharm, Illumina's strategic partner in Russia and the Commonwealth of Independent States (CIS), led the regulatory process, which requires separate approvals of sequencing platforms and reagents by the Russian medical device regulatory agency, Roszdravnadzor.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.